International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea ...

The partnership will leverage Neomorph’s molecular glue discovery platform. Credit: PeopleImages.com – Yuri A/Shutterstock. Biogen and Neomorph have entered a research partnership aimed at discovering ...

REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and ...

Announced that World Health Organization (WHO) has approved "icovamenib" as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States Adopted ...

Announced that World Health Organization (WHO) has approved“icovamenib” as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States ...

BOSTON, MA, USA I October 24, 2024 I BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its ...

Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development ...

Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cellsREDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- ...

for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted "icovamenib" as the United States Adopted Name (USAN) for BMF-219. The suffix '-menib' stands ...

for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted “icovamenib” as the United States Adopted Name (USAN) for BMF-219. The suffix ‘-menib ...